Keyphrases
Haploidentical Hematopoietic Stem Cell Transplantation
71%
Cytokine Release Syndrome
63%
Peripheral Blood
59%
Graft-versus-host Disease (GvHD)
58%
Post-transplantation Cyclophosphamide (PTCy)
38%
Haploidentical Transplantation
29%
Acute Myeloid Leukemia
28%
Unrelated Donor
28%
Overall Survival
25%
Haploidentical
22%
Graft-versus-host Disease Prophylaxis
21%
Janus Kinase Inhibitors
21%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
19%
Pretransplant
19%
Hematopoietic Cell Transplant
17%
Cell Therapy
16%
Mismatched Related Donor
16%
Tocilizumab
14%
Early Mortality
14%
Transplantation Therapy
14%
Leukemia Therapy
14%
Letermovir
14%
Melphalan Conditioning
14%
Cell Transplant
14%
Skin Transplantation
14%
Donor Relationships
14%
Heart Transplant
14%
High Tumor Burden
14%
Donor Type
14%
In Silico Screening
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
SLAMF7
14%
Peripheral Blood Cells
14%
Acute Graft Rejection
14%
CD8+
14%
Baricitinib
14%
Myeloma
14%
Bloodstream Infection
14%
Donor Age
14%
Reduced Intensity
14%
Cytomegalovirus
14%
Transplantation Model
14%
Fludarabine
14%
Cyclosporine
14%
Fratricide
14%
Leukemia Stem Cells
14%
Poor Survival
14%
Gene Expression Data
14%
Desensitization
14%
Immunoglobulin
14%
Immunology and Microbiology
Hematopoietic Cell
100%
Cell Transplantation
85%
Cytokine Release Syndrome
73%
Graft-Versus-Host Disease
61%
Cyclophosphamide
30%
Overall Survival
26%
Conditioning
21%
Engraftment
14%
Tocilizumab
14%
Chimeric Antigen Receptor T-Cell Therapy
14%
Hemocyte
14%
Ciclosporin
14%
CD8
14%
Chimeric Antigen Receptor T-Cell
14%
Tumor Volume
14%
Acute Graft Rejection
14%
Hematopoietic Stem Cell Transplantation
14%
Blood Flow
14%
Cytomegalovirus
14%
Stem Cell Transplant
14%
Myeloid
14%
Intravenous Immunoglobulin
14%
Plasmapheresis
14%
HLA Antibody
14%
Acute Graft Versus Host Disease
13%
Chronic Graft Versus Host Disease
7%
T Cell
7%
Histocompatibility
7%
Neutrophil
6%
Recurrence Free Survival
6%